Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa serotype O11 from drug addicts. 1985

K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins

The growth of Pseudomonas aeruginosa, particularly serotype O11, in pentazocine and tripelennamine ("T's and Blues") was evaluated as a possible explanation for the association of deep-seated infection with this organism and abuse of these drugs. The mean reduction of growth caused by the drugs was 1,000-fold greater for 49 Pseudomonas strains from normal subjects than for 32 strains from drug addicts (4.2 vs. 1.3 logs of reduction at 2 hr, P less than .0005). A common phenotypic subset of the serotype O11 strains from drug addicts was especially resistant to the inhibitory effects. Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. We conclude that an ability of some P. aeruginosa serotype O11 strains, but not S. aureus, to survive in pentazocine and tripelennamine may explain in part a shift from S. aureus to P. aeruginosa as common pathogens of drug addicts in areas where abuse of this combination of drugs has increased.

UI MeSH Term Description Entries
D010423 Pentazocine The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) Fortral,Lexir,Pentazocine Hydrochloride,Pentazocine Lactate,Talwin,Hydrochloride, Pentazocine,Lactate, Pentazocine
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012703 Serotyping Process of determining and distinguishing species of bacteria or viruses based on antigens they share. Serotypings
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D014309 Tripelennamine A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat ASTHMA; HAY FEVER; URTICARIA; and RHINITIS; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. Azaron,Histantin,Pyribenzamine,Tripelennamine Citrate,Tripelennamine Citrate (1:1),Tripelennamine Hydrochloride,Tripelennamine Maleate,Tripelennamine Maleate (1:1),Tripelennamine Monohydrochloride,Vetibenzamin
D019966 Substance-Related Disorders Disorders related to substance use or abuse. Chemical Dependence,Drug Abuse,Drug Addiction,Drug Dependence,Drug Habituation,Drug Use Disorder,Drug Use Disorders,Organic Mental Disorders, Substance-Induced,Substance Abuse,Substance Dependence,Substance Related Disorder,Substance Use,Substance Use Disorder,Substance Use Disorders,Prescription Drug Abuse,Substance Addiction,Abuse, Drug,Abuse, Prescription Drug,Abuse, Substance,Addiction, Drug,Addiction, Substance,Chemical Dependences,Dependence, Chemical,Dependence, Drug,Dependence, Substance,Dependences, Chemical,Disorder, Drug Use,Disorder, Substance Related,Disorder, Substance Use,Disorders, Substance Related,Drug Abuse, Prescription,Habituation, Drug,Organic Mental Disorders, Substance Induced,Related Disorder, Substance,Related Disorders, Substance,Substance Abuses,Substance Uses,Use, Substance

Related Publications

K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
February 1985, The Journal of infectious diseases,
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
October 1984, Journal of clinical microbiology,
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
January 1995, Infection,
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
November 1974, American heart journal,
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
November 1980, The International journal of the addictions,
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
February 2024, Antibiotics (Basel, Switzerland),
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
November 1981, The Journal of infectious diseases,
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
September 1992, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
June 1990, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
K B Botsford, and R A Weinstein, and C R Nathan, and S A Kabins
April 1978, JAMA,
Copied contents to your clipboard!